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Abstract 
AIM
To explore the effect of primary liver disease and 
comorbidities on transplant length of stay (TLOS) and 
LOS in later admissions in the first two years after liver 
transplantation (LLOS).  
METHODS
A linked United Kingdom Liver Transplant Audit - Hospital 
Episode Statistics database of patients who received a first 
adult liver transplant between 1997 and 2010 in England 
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was analysed. Patients who died within the first two years 
were excluded from the primary analysis, but a sensitivity 
analysis was also performed including all patients. 
Multivariable linear regression was used to evaluate the 
impact of primary liver disease and comorbidities on TLOS 
and LLOS. 
RESULTS
In 3772 patients, the mean (95%CI) TLOS was 24.8 (24.2 
to 25.5) d, and the mean LLOS was 24.2 (22.9 to 25.5) 
d. Compared to patients with cancer, we found that the 
largest difference in TLOS was seen for acute hepatic 
failure group (6.1 d; 2.8 to 9.4) and the largest increase 
in LLOS was seen for other liver disease group (14.8 d; 
8.1 to 21.5). Patients with cardiovascular disease had 8.5 
d (5.7 to 11.3) longer TLOS and 6.0 d (0.2 to 11.9) longer 
LLOS, compare to those without. Patients with congestive 
cardiac failure had 7.6 d longer TLOS than those without. 
Other comorbidities did not significantly increase TLOS 
nor LLOS.
CONCLUSION
The time patients spent in hospital varied according to 
their primary liver disease and some comorbidities. Time 
spent in hospital of patients with cancer was relatively 
short compared to most other indications. Cardiovascular 
disease and congestive cardiac failure were the comor-
bidities with a strong impact on increased LOS. 
Key words: Length of stay; Hospital stay; Comorbidity; 
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Core tip: Time patients spent in hospital in transplant 
admission and in later admissions after liver trans-
plantation may reflect the success of liver transplantation. 
By analysing a linked United Kingdom Liver Transplant 
Audit - Hospital Episode Statistics database between 1997 
and 2010, we found that average transplant length of stay 
(LOS) was 24.8 d, and mean LOS of all admissions in the 
first two years after transplantation was 24.2 d. Primary 
liver disease and comorbidities had a significant impact 
on LOS. Patients transplanted for cancer has shorter LOS 
compared to other indications. Cardiovascular disease and 
congestive cardiac failure were associated with increased 
LOS.
Tovikkai C, Charman SC, Praseedom RK, Gimson AE, van der 
Meulen J. Time spent in hospital after liver transplantation: Effects 
of primary liver disease and comorbidity. World J Transplant 
2016; 6(4): 743-750  Available from: URL: http://www.wjgnet.
com/2220-3230/full/v6/i4/743.htm  DOI: http://dx.doi.org/10.5500/
wjt.v6.i4.743
INTRODUCTION
The short-term and long-term survival after liver 
transplantation has been improving over the last few 
decades. However, length of stay (LOS) is another 
outcome that reflects the success of liver transplantation. 
Transplant LOS (TLOS) has also been one of the main 
outcomes in investigating health care resource use in 
organ transplantation. Identifying variables predicting 
longer LOS will help clinicians plan hospital resources in 
advance, and maximise the resource utilisation. LOS in 
transplant admission can also reliably reflect the cost of 
liver transplant admission[1]. 
There are several studies report risk factors pre-
dicting longer transplant LOS[2-9]. Recipient factors 
(e.g., age, sex, liver disease severity, retransplantation, 
pre-transplant nutritional status, pre-transplant renal 
support), donor factors (e.g., age, weight, non-local 
donor centre) and early post-transplant complications 
and graft dysfunction have been shown to be associated 
with prolonged transplant LOS. LOS also varies between 
liver transplant centres[4,5]. Nevertheless, primary liver 
disease and comorbidities have rarely been investigated 
in terms of their effects on LOS. Moreover, the previous 
studies were based on only single or few centres, and the 
cohort sizes were often limited. In this study, we used 
a national clinical database linked to an administrative 
hospital database in England to investigate LOS in a 
larger national cohort of liver transplant patients.
LOS in later admissions after liver transplantation 
may reflect quality of life after liver transplantation and 
represent the success of liver transplantation. More-
over, it can reflect the healthcare resource use in the 
maintenance period after liver transplantation. To the 
best of our knowledge, there has not been any study in 
this topic.
In this study, we aim to investigate the effect of 
primary liver disease and pre-transplant comorbidities on 
TLOS as these two important factors have rarely been 
studied. The secondary aim is the effect of these factors 
on LOS in later admissions (LLOS) in the first two years 
after liver transplantation.
MATERIALS AND METHODS
The linked UKLTA-HES database
Records from the United Kingdom Liver Transplant 
Audit (UKLTA) database linked at a patient level to 
Hospital Episode Statistics (HES) records were used in 
this study. The UKLTA database prospectively collects 
liver transplant-specific data for all patients undergoing 
liver transplantation in the United Kingdom for audit 
purposes[10]. The HES database is an administrative 
hospital database of all admissions to National Health 
Service (NHS) hospitals in England[11]. A HES record 
contains the tenth revision of the International 
Classification of Diseases (ICD-10) diagnosis codes[12], 
procedure codes, admission method as well as length 
of hospital stay based on date of admission and date of 
discharge. The linkage process was based on hierarchical 
deterministic linkage criteria, including NHS number, 
sex, date of birth, postcode, date of transplant and a 
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procedure code for liver transplantation or a diagnosis 
code relevant to liver disease. A detailed description of 
the linkage process has been published elsewhere[13]. 
This linked database contained records of patients 
receiving a first liver transplant in England between 1st 
April 1997 and 31st March 2010. We excluded linked 
records of paediatric liver transplantation (younger than 
17 years), multi-organ transplantation, living-donor 
liver transplantation and domino liver transplantation. 
To avoid the interference from the short LOS in patients 
who died early after transplantation, the patients who 
died within the first two years after liver transplantation 
(718 patients) were also excluded from the primary 
analysis. However, a sensitivity analysis for the whole 
cohort was also performed. At least two years follow-up 
was available for all included patients.
LOS information
LOS information was obtained from the HES database. 
TLOS was calculated from date of transplant to date of 
discharge, while LOS of a later admission was calculated 
from date of admission to date of discharge. LOS of all 
later admissions in the first two years after transplantation 
(LLOS) was defined as a sum of LOS of every admission in 
any NHS hospital in England that had an admission date 
within the first two years from the date of transplant.
Statistical analysis
Unadjusted TLOS and LLOS of patients in each primary 
liver disease group and of patients with each comorbidity 
were compared using unpaired two-tailed Student’s 
t-test and analysis of variance (ANOVA) as appropriate. 
Primary liver diseases were categorised into ten indication 
groups according to Roberts et al[14], including one 
group with less common indications grouped together 
as the other liver diseases group. Eight comorbidities 
were identified from ICD-10 diagnosis codes in HES 
based on the adaptation of the Royal College of 
Surgeons Charlson Score for liver transplantation[15]. 
Cardiovascular comorbidity comprises of a history of 
myocardial infarction, peripheral vascular disease and 
cerebrovascular disease. 
Multivariable linear regression analysis was per-
formed to determine the effects of the individual variables 
on TLOS and LLOS, taking into account other baseline 
characteristics, severity of liver disease and transplant 
centres. Variables included in the model were 10-group 
primary liver disease, all eight comorbidities, recipient 
age, sex, serum bilirubin, creatinine, sodium and in-
ternational normalised ratio (INR) of prothrombin 
time (factors reflecting the severity of liver disease), 
liver transplant centre and time period of liver trans-
plantation. Serum bilirubin and creatinine were log-
transformed before inputting into the model to improve 
the linearity of the relationship between these factors 
and LOS. The comorbidities and sex were included as 
binary variables, while primary liver disease groups, 
transplant centre and time period of liver transplantation 
were entered as categorical variables. The remaining 
variables were included as continuous variables.
LOS may not only depend on disease and patient 
factors, such as type and severity of liver disease 
and comorbidities, but also on hospital policy that 
may change over time. Therefore, we included the 
information about individual transplant centre and time 
period of liver transplantation in the models.
The ten primary liver disease groups were mutually 
exclusive. In the multivariable models, coefficients of 
primary liver disease groups were compared to cancer 
group as a reference group because it was one of the 
most common and shortest LOS groups. To make 
the comparison easier to interpret, we also presented 
adjusted mean LOS, which reflects LOS for these groups 
after taking other variables into account. The adjusted 
mean TLOS and LLOS for patients in each of the primary 
liver disease groups were calculated based on the 
prediction from multivariable linear regression models 
and presented along with their 95% confidence intervals 
(CI). This represents the LOS according to primary liver 
disease groups with an average case-mix profile of other 
variables in the model.
To ensure that patients with missing values were 
not excluded from the analyses, missing values were 
imputed with ten plausible data sets using multiple 
imputation with chain equations technique[16]. The ten 
completed data sets were individually analysed, and 
estimates were then pooled to give final estimates using 
Rubin’s rules[17]. However, all of the variables in the model 
had missing values for less than 5% of the patients. All 
statistical analyses were performed using Stata version 
11.2 (StataCorp, College Station, TX, United States). 
A P-value of less than 0.05 was considered statistically 
significant.
Sensitivity analysis
The primary analysis included only patients who survived 
the first two years after transplantation as the patients 
who died early after transplantation would shorten the 
average of LOS. A sensitivity analysis for TLOS was 
performed using the whole cohort including patients who 
died in the first two years after transplantation (4490 
patients). 
RESULTS
Demographic characteristics
The data used in this study were from 3772 adult 
patients who had a first liver transplant in England from 
April 1997 to March 2010 and survived the first two 
years after liver transplantation. The median (interquartile 
range: IQR) age was 52 (42 to 59) years, and 58.7% 
of the patients were male. The most common indication 
for liver transplantation was alcoholic cirrhosis (20.0%), 
followed by cancer (13.9%) and primary biliary cirrhosis 
(13.4%). The most common comorbidity was diabetes 
mellitus with a prevalence of 20.8%, followed by chronic 
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alcoholic fatty liver disease (4.3 d longer) and hepatitis 
C cirrhosis (3.9 d longer) groups had significantly longer 
TLOS than the baseline. As for LLOS, other liver disease 
(14.8 d longer) and primary sclerosing cholangitis (8.4 
d longer) were significantly associated with longer LLOS 
than the baseline (Table 3).
Figure 1 presents the same above results using 
adjusted means for TLOS and LLOS, and further illustrates 
that patients with acute hepatic failure, hepatitis C 
cirrhosis, metabolic and non-alcoholic fatty liver disease 
and other liver disease had longer than average TLOS 
and LLOS, although not all significantly so. Whereas, 
patients with liver diagnosis of cancer, primary biliary 
cirrhosis, alcoholic cirrhosis and autoimmune hepatitis and 
cryptogenic cirrhosis groups had shorter than average 
TLOS and LLOS. Of note, primary sclerosing cholangitis 
was associated with shorter TLOS, but significantly longer 
LLOS (Figure 1).
LOS according to comorbidities 
Patients with atherosclerotic cardiovascular disease had 
the longest unadjusted TLOS at 33 d, and those with 
chronic renal disease had the longest unadjusted LLOS 
at 32 d (Table 2). The multivariable linear regression 
analysis demonstrated that cardiovascular disease and 
congestive cardiac failure were significantly associated 
with longer TLOS. Patients with cardiovascular disease 
spent an average of 8.5 d longer in transplant admission 
than those without the comorbidity, and those with a 
history of congestive cardiac failure spent 7.6 d longer 
than those without, confirming what previously observed 
in unadjusted LOS (Table 3).
Patients with cardiovascular disease spent signi-
ficantly longer time in hospital in the first two years after 
transplantation than those without the comorbidity (6.0 
d longer). Those with chronic renal disease and chronic 
pulmonary disease spent 4.8 d and 4.3 d longer than 
those without the comorbidities, respectively, albeit not 
statistically significant (Table 3). 
Sensitivity analysis of TLOS including patients who died 
in the first two years after liver transplantation
After including 718 patients who died within the first 
two years after transplantation, the sensitivity analysis 
of 4490 patients found that primary liver disease, 
cardiovascular disease and congestive cardiac failure 
remained statistically significant in predicting TLOS. In 
terms of primary liver disease groups, patients in other 
liver disease group had the longest TLOS, followed by 
acute hepatic failure group. Cardiovascular disease were 
associated with 8.7 d longer TLOS than those without 
the comorbidity, while patients with congestive cardiac 
failure had 7.7 d longer TLOS than those without, which 
were similar to those in the primary analysis (Table 4).
DISCUSSION
Liver transplant recipients spent in total 49 d in 
hospital during the first two years after transplantation, 
pulmonary disease (9.1%) and chronic renal disease 
(6.6%) (Table 1). In terms of pre-transplant status, 
74.0% of the patients were at home, while 16.0% 
were in hospital but not ventilated, and 10.0% were 
hospitalised and ventilated at the time of transplantation. 
Some 4.7% of the patients received a liver graft from 
donation after cardiac death. 
Overall LOS
Overall, patients spent an average of 24.8 d (95%CI: 24.2 
to 25.5) in hospital during their transplant admission, and 
24.2 d (22.9 to 25.5) in later admissions in the first two 
years after transplantation (Table 2). 
LOS according to primary liver diseases 
Primary liver disease groups were significant predictors 
of both TLOS and LLOS (Table 2). Using cancer group 
as a baseline, the multivariable analysis demonstrated 
that patients in acute hepatic failure (6.1 d longer), 
other liver disease (5.9 d longer), metabolic and non-
Table 1  Demographic characteristics of the adult recipients 
of a first liver transplant in England who survived the first two 
years after transplantation
Characteristic Value Missing (n)
Number 3772
Age (yr) 52 (42-59)     0
Sex (%)     0
   Male 2214 (58.7)
   Female 1558 (41.3)
Primary liver disease (%)     0
   Cancer 525 (13.9)
   Acute hepatic failure 455 (12.1)
   Hepatitis C cirrhosis 392 (10.4)
   Primary sclerosing cholangitis 354 (9.4)
   Hepatitis B cirrhosis 98 (2.6)
   Primary biliary cirrhosis 507 (13.4)
   Alcoholic cirrhosis 753 (20.0)
   Autoimmune and cryptogenic cirrhosis 348 (9.2)
   Metabolic liver disease 107 (2.8)
   Other liver disease 233 (6.2)
Comorbidities (%)
   Cardiovascular disease 200 (5.3)     0
   Congestive cardiac failure 82 (2.2)     0
   Connective tissue disease 134 (3.6)     0
   Dementia 159 (4.2)     0
   Diabetes mellitus 784 (20.8)     0
   Non-hepatic malignancy 40 (1.1)     0
   Chronic pulmonary disease 344 (9.1)     0
   Chronic renal disease 247 (6.6)     0
Era of liver transplantation (%)     0
   April 1997 - September 2000 841 (22.3)
   October 2000 - September 2003 899 (23.8)
   October 2003 - September 2006 897 (23.8) 
   October 2006 - March 2010 1135 (30.1)
Bilirubin (µmol/L) 54 (27-124)   20
Creatinine (µmol/L) 89 (74-109)     2
INR 1.4 (1.2-1.8) 162
Sodium (mmol/L) 137 (134-140)     8
UKELD score 55 (51-59) 184
Results are numbers (percentages) or medians (interquartile ranges). INR: 
International normalised ratio; UKELD: United Kingdom End-stage Liver 
Disease.
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approximately half in the transplant admission and 
the other half in subsequent admissions. However, the 
LOS was affected by primary liver disease and some 
comorbidities. Patients with liver diagnosis in acute hepatic 
failure, hepatitis C cirrhosis and other liver disease groups 
had a longer TLOS than those in any other groups, while 
patients in primary sclerosing cholangitis and other 
liver disease groups had longer LLOS. Patients with 
Table 2  Unadjusted transplant length of stay and length of stay in later admissions in the first two years after liver transplantation 
regarding primary liver disease and comorbidities
Variable n  (%) Unadjusted TLOS Unadjusted LLOS 
(d) 95%CI P -value (d) 95%CI P -value
Overall average 3772 25 24-26 N/A 24 23-26 N/A
Primary liver disease groups
  Cancer 525 (13.9) 22 20-24 < 0.001 22 18-25 < 0.001
  Acute hepatic failure 455 (12.1) 33 32-35 26 22-30
  Hepatitis C cirrhosis 392 (10.4) 27 25-29 26 22-30
  Primary sclerosing cholangitis 354 (9.4) 23 20-25 27 23-31
  Hepatitis B cirrhosis 98 (2.6) 22 18-26 21 13-29
  Primary biliary cirrhosis 507 (13.4) 21 20-23 20 16-23
  Alcoholic cirrhosis 753 (20.0) 24 23-26 22 19-25
  Autoimmune and cryptogenic 348 (9.2) 22 20-24 23 18-27
  Metabolic liver disease 107 (2.8) 26 22-30 29 21-37
  Other liver disease 233 (6.2) 28 26-31 37 32-42
Comorbidities
  Cardiovascular disease 200 (5.3) 33 28-39 < 0.001 31 24-38 0.02
  Congestive cardiac failure 82 (2.2) 32 24-39 0.003 18 13-24 0.18
  Connective tissue disease 134 (3.6) 22 20-25 0.13 25 18-32 0.91
  Dementia 159 (4.2) 25 21-28 0.87 26 21-32 0.54
  Diabetes mellitus 784 (20.8) 24 23-26 0.42 26 23-29 0.18
  Non-hepatic malignancy 40 (1.1) 23 17-29 0.65 24 10-37 0.91
  Chronic pulmonary disease 344 (9.1) 27 25-30 0.04 28 24-33 0.06
  Chronic renal disease 247 (6.6) 27 23-30 0.17 32 25-38 0.003
TLOS: Transplant length of stay; LLOS: Later length of stay; N/A: Not applicable.
Table 3  Multivariable linear regression analysis for transplant length of stay and later length of stay in the first two years after liver 
transplantation
Variable value Coefficient for TLOS Coefficient for LLOS 
(d) 95%CI P -value (d) 95%CI P -value
Primary liver disease groups1
  Cancer 0 Reference < 0.001 0 Reference < 0.001
  Acute hepatic failure 6.1 2.8, 9.4 4 -3.3, 11.3
  Hepatitis C cirrhosis 3.9 1.3, 6.4 5.4 -0.1, 10.9
  Primary sclerosing cholangitis 0.2 -2.5, 3.0 8.4 2.6, 14.3
  Hepatitis B cirrhosis 1.9 -2.3, 6.1 1 -7.9, 9.9
  Primary biliary cirrhosis -0.5 -3.2, 2.1 0.2 -5.6, 5.9
  Alcoholic cirrhosis 0.6 -1.6, 2.8 0.6 -4.1, 5.4
  Autoimmune and cryptogenic 0.1 -2.6, 2.9 1.4 -4.4, 7.2
  Metabolic liver disease 4.3 0.3, 8.4 7.1 -1.5, 15.7
  Other liver disease 5.9 2.8, 9.1 14.8 8.1, 21.5
Comorbidities2
  Cardiovascular disease 8.5 5.7, 11.3 < 0.001 6 0.2, 11.9 0.04
  Congestive cardiac failure 7.6 3.4, 11.8 < 0.001 -5 -14.0, 3.9 0.27
  Connective tissue disease -1.4 -4.8, 2.0 0.42 2.3 -4.9, 9.5 0.54
  Dementia 0.2 -2.9, 3.4 0.87 3.6 -3.1, 10.4 0.29
  Diabetes mellitus 1 -0.6, 2.6 0.22 2.6 -0.8, 6.0 0.13
  Non-hepatic malignancy -0.7 -6.7, 5.3 0.82 -0.5 -13.2, 12.2 0.94
  Chronic pulmonary disease 1.6 -0.5, 3.8 0.14 4.3 -0.2, 8.9 0.06
  Chronic renal disease 1 -1.6, 3.5 0.47 4.8 -0.7, 10.3 0.09
1A coefficient for primary liver disease groups represents a difference in days between LOS of patients in the primary liver disease group and the 
reference group (cancer); 2A coefficient for comorbidities represents a difference in days between LOS of patients with and without the comorbidity. The 
multivariable models were adjusted for primary liver disease group, comorbidities, recipient age, sex, log bilirubin, log creatinine, INR, sodium, transplant 
centre and time of transplantation. TLOS: Transplant length of stay; LLOS: Later length of stay.
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cardiovascular disease and cardiac failure also had longer 
TLOS than those without these comorbidities, and patients 
with cardiovascular disease spent longer time in later 
admissions than those without.
In terms of primary liver disease, acute hepatic 
failure, hepatitis C cirrhosis and other liver disease were 
associated with longer TLOS. Patients with acute hepatic 
failure are mostly intubated and ventilated and on renal 
replacement therapy[18]. Therefore, it is not unexpected 
that they required more time to recover from the liver 
transplant operation. Hepatitis C cirrhosis may be related 
to more complications after liver transplantation, and 
this is probably the reason why patients transplanted for 
this indication spent longer time in transplant admission. 
The group of patients with other liver disease is the 
most heterogeneous group of patients with a wide range 
of liver diagnoses, consisting mainly of Budd-Chiari 
syndrome, secondary biliary cirrhosis and polycystic liver 
disease. Thus, the reason why these patients had longer 
LOS needs further investigation. 
Patients with primary sclerosing cholangitis had 
relatively shorter TLOS, but relatively longer LLOS. These 
discrepancies may be a result of a higher rate of recurrent 
disease, vascular complications or conditions related to 
ulcerative colitis that need admissions for interventions or 
procedures[19]. Nevertheless, the reasons for readmissions 
can be either transplant-related or non-transplant-related, 
and they were not explored in this study.
With respect to comorbidities, common comorbidities, 
such as diabetes, chronic pulmonary and renal disease, 
showed no impact on TLOS, while less common comor-
bidities, such as cardiovascular disease and congestive 
cardiac failure, were found to have an impact on TLOS. 
Cardiovascular disease, which is the grouping of three 
comorbid conditions in the same disease spectrum 
(myocardial infarction, peripheral vascular disease and 
cerebrovascular disease), was significantly associated with 
longer TLOS as was congestive cardiac failure. We have 
shown elsewhere that a previous history of cardiovascular 
disease and cardiac failure were also associated with 
Table 4  Sensitivity analysis of the multivariable linear regression 
for transplant length of stay including patients who died within 
the first two years after liver transplantation (4490 patients)
Variable Coefficient for TLOS
(d) 95%CI P -value
Primary liver disease groups1
  Cancer 0.0 Reference 0.001
  Acute hepatic failure 3.7 0.2, 7.2
  Hepatitis C cirrhosis 3.3 0.6, 6.1
  Primary sclerosing cholangitis -0.3 -3.2, 2.7
  Hepatitis B cirrhosis 0.6 -4.0, 5.2
  Primary biliary cirrhosis -1.5 -4.4, 1.4
  Alcoholic cirrhosis 1.1 -1.3, 3.5
  Autoimmune and cryptogenic 0.5 -2.5, 3.4
  Metabolic liver disease 3.3 -0.9, 7.6
  Other liver disease 5.9 2.5, 9.2
Comorbidities2
  Cardiovascular disease 8.7 5.8, 11.5 < 0.001
  Congestive cardiac failure 7.7 3.6, 11.8 < 0.001
  Connective tissue disease -0.3 -4.0, 3.3 0.86
  Dementia 1.1 -2.4, 4.6 0.54
  Diabetes mellitus 1.1 -0.6, 2.8 0.21
  Non-hepatic malignancy 0.9 -4.6, 6.3 0.76
  Chronic pulmonary disease 1.2 -1.1, 3.5 0.3
  Chronic renal disease 1.7 -1.0, 4.4 0.22
1A coefficient for primary liver disease groups represents a difference in 
days between LOS in the primary liver disease group and the reference 
group (cancer); 2A coefficient for comorbidities represents a difference 
in days between LOS of patients with and without the comorbidity. 
The multivariable model was adjusted for primary liver disease group, 
comorbidities, recipient age, sex, log bilirubin, log creatinine, INR, sodium, 
transplant centre and time period of transplantation. TLOS: Transplant 
length of stay; INR: International normalised ratio.
Cancer
Acute
HCV
PSC
HBV
PBC
ALD
AIH
Metabolic
Other
Overall
Cancer
Acute
HCV
PSC
HBV
PBC
ALD
AIH
Metabolic
Other
Overall
15            20           25            30           35
Transplant LOS, days
Adjusted LOS
Overall LOS
95%CI
95%CI
15            20           25            30           35
LOS in later admissions, days
Figure 1  Adjusted transplant length of stay and length of stay in later admissions in the first 2 years after liver transplantation according to primary liver 
disease. HCV: Hepatitis C cirrhosis; PSC: Primary sclerosing cholangitis; HBV: Hepatitis B cirrhosis; PBC: Primary biliary cirrhosis; ALD: Alcoholic liver disease; AIH: 
Autoimmune hepatitis and cryptogenic cirrhosis; LOS: Length of stay.
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higher 90-d mortality[15]. This study further showed that 
these groups of high-risk patients also used more health 
resources during their transplant admission. This is 
probably because of a higher risk of cardiac complications 
following a hemodynamically stressful liver transplant 
operation in these already compromised patients. 
A previous single-centre study carried out in the 
United States with only 83 patients found that multi-
vessel coronary artery disease is associated with higher 
mortality, increased LOS and post-operative vasopressor 
requirements[20], which is in line with the results found 
in our national cohort in England. In addition, we demon-
strated that the LOS in later admissions in the first two 
years in patients with atherosclerotic cardiovascular 
disease was also longer, particularly in those who 
survived the first two years. This reflects that these 
patients with cardiovascular comorbidity have a higher 
mortality risk and require more healthcare resources 
during transplant admissions as well as the early period 
after liver transplantation.
Our results have a number of implications for clinical 
practice. First, LOS of the transplant admission and 
of later admissions can be an alternative marker of 
outcomes after liver transplantation, especially in the era 
that graft and patient survival after liver transplantation 
have been excellent. LOS in later admissions after liver 
transplantation may also reflect the quality of life and 
functional status of a patient after transplantation. A 
successful liver transplantation should return a patient 
back to the healthy status with as few admissions 
after transplantation as possible. Second, the ability to 
estimate LOS may be beneficial to the pre-transplant 
counselling process as it can help to inform patients and 
their relatives what to expect after liver transplantation. 
Third, another benefit of estimating LOS is that it 
would help clinicians and hospitals plan their resource 
utilisation and bed management. For example, patients 
transplanted for cancer spent, on average, a total of 44 
d in the first two years after transplantation, whereas 
patients who were transplanted with an indication in 
other liver disease group, such as Budd-Chiari syndrome, 
had a total LOS that was 50% longer (66 d) (Figure 1). 
Fourth, our results can improve economic evaluations 
of liver transplantation as it provides more accurate 
estimates of LOS for patients with comorbidities.
We note a number of limitations of this study. Firstly, 
we have not explored the reasons for later admissions. 
It may be beneficial to understand the indication for 
readmissions in particular groups of patients, and this 
may warrant further research. Secondly, this study 
includes only patients who had a first liver transplant. 
It is known that the outcomes of retransplantation are 
much different to those of first liver transplantation[21]. 
Retransplantation has also been shown to be associated 
with longer transplant LOS[4].
Conclusion
We have shown that the time patients spent in hospital 
after liver transplantation is linked to primary liver 
disease and comorbidities. LOS was relative short for 
patient who had a liver transplant for cancer whereas 
the opposite was true for patients with atherosclerotic 
cardiovascular disease and congestive cardiac failure.
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COMMENTS
Background
Time patients spent in hospital after transplantation is directly related with 
health care resource use and partly reflects the success of liver transplantation. 
Identifying factors predicting longer length of stay will help clinicians and 
hospitals to plan and maximise the resource utilisation.
Research frontiers
Several recipient and donor factors have been found to be associated with 
prolonged transplant length of stay. However, primary liver disease and 
comorbidities have rarely been investigated in this issue. Length of stay in 
later admissions after transplantation also reflects quality of life after liver 
transplantation and can represent the success of liver transplantation. This has 
never been investigated in liver transplantation. 
Innovations and breakthroughs
Based on the United Kingdom national liver transplant cohort, the authors 
demonstrated that transplant length of stay was affected by primary liver 
disease and comorbidities. Patients with acute hepatic failure, hepatitis C 
cirrhosis, atherosclerotic cardiovascular disease and a history of congestive 
cardiac failure stayed longer in hospital in their transplant admissions, while 
patients with primary sclerosing cholangitis spent more time in subsequent 
admissions in the first two years after liver transplantation.
Applications
Estimating length of stay will help clinicians and hospitals plan their health 
care resource utilisation including bed management. Moreover, knowing the 
estimated length of stay will be beneficial to the pre-transplant counselling 
process. It can help inform patients and relatives what they expect after 
liver transplantation. Finally, in the era that graft and patient survival after 
liver transplantation have been excellent, length of stay of the transplant 
admission and of later admissions can be a surrogate of outcomes after liver 
transplantation. Length of stay in later admissions after liver transplantation also 
specifically reflects the quality of life of patients after transplantation and the 
success of liver transplantation as it should return a patient back to the healthy 
status with as few admissions after transplantation as possible. 
Terminology
Transplant length of stay (TLOS) was calculated from date of transplant to 
date of discharge, not including time patients spent in hospital in the pre-
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transplant period. Length of stay in later admissions was a sum of length of 
stay of every admission in any National Health Service hospital in England that 
had an admission date within the first two years from the date of transplant. 
Cardiovascular comorbidity comprises of a history of myocardial infarction, 
peripheral vascular disease and cerebrovascular disease coded in the 
administrative hospital database in any previous admission in the preceding 
year before the transplant. Congestive cardiac failure is defined by a history 
of congestive cardiac failure coded in the administrative hospital database in 
any previous admission in the preceding year before the transplant. Other liver 
disease is a group of indications for liver transplantation that is consisted of less 
common indications grouped together. It is the most heterogenous group of 
indications, including mainly Budd-Chiari syndrome, secondary biliary cirrhosis 
and polycystic liver disease.
Peer-review
This study investigated the time after surgery after liver transplantation. The aim 
was clear, and methods were appropriate.
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